Comparative Pharmacology
Head-to-head clinical analysis: DEPACON versus DIVALPROEX SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPACON versus DIVALPROEX SODIUM.
DEPACON vs DIVALPROEX SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases GABA concentration in the brain by inhibiting GABA transaminase and blocking voltage-gated sodium channels.
Increases brain concentrations of gamma-aminobutyric acid (GABA), blocks voltage-gated sodium channels, and modulates T-type calcium channels.
10-15 mg/kg/day IV or orally divided every 8 hours; maximum 60 mg/kg/day.
10-15 mg/kg/day orally in divided doses; increase by 5-10 mg/kg/week; maximum 60 mg/kg/day. Extended-release: 25 mg/kg/day orally; increase by 15 mg/kg/day at weekly intervals; maximum 60 mg/kg/day.
None Documented
None Documented
10–16 hours; neonates 20–30 hours; patients with liver disease up to 18 hours; decreased half-life in patients on enzyme-inducing antiepileptics (e.g., phenytoin, carbamazepine) to 4–9 hours.
9-16 hours (terminal); shorter in children (6-9 hours) and longer in hepatic disease or elderly; clinical context: twice-daily dosing provides stable trough concentrations.
Primarily renal: >90% of a dose is excreted in urine as valproic acid glucuronide (30–50%), 3-oxo-valproic acid (30–40%), and other metabolites. Less than 3% excreted unchanged. Minor fecal elimination (≈5%).
Renal: <3% unchanged; primarily hepatic metabolism (glucuronidation, beta-oxidation, cytochrome P450), metabolites eliminated renally; fecal: negligible.
Category C
Category D/X
Anticonvulsant
Anticonvulsant